Severe bullous disorders, KELA reimbursement

L12_PEMPHIKELA

vesiculobullous skin disease: Skin diseases characterized by local or general distributions of vesicles and bullae (i.e. blisters). Both vesicles and bullae are fluid-filled lesions, distinguished by size (vesicles being less than 5–10 mm and bullae being larger than 5–10 mm). Vesiculobullous diseases are classified according to the site and mode of blister formation. Lesions can appear spontaneously or be precipitated by infection, trauma, or sunlight. Etiologies include immunologic and genetic factors. In the case of vesiculobullous diseases which are also immune disorders, the term immunobullous is sometimes used. (From Scientific American Medicine, 1990, and Wikipedia)

Endpoint definition

FinnGen phenotype data

321302 individuals

diagram downward connector

Apply sex-specific rule None

321302

diagram downward connector

Check conditions None

321302

diagram downward connector
diagram bullet

Filter registries

KELA reimbursements: KELA codes 135

32

diagram downward connector

Check pre-conditions, main-only, mode, ICD version None

32

diagram downward connector

Check minimum number of events None

32

diagram downward connector

Include endpoints None

32

diagram downward connector
L12_PEMPHIKELA

Extra metadata

Level in the ICD hierarchy 3
First used in FinnGen datafreeze DF2

Summary Statistics

Key figures

All Female Male
Number of individuals 31 15 16
Unadjusted prevalence (%) 0.01 0.01 0.01
Mean age at first event (years) 58.72 57.94 59.46

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 - - - -
15 years - - - -
5 years - - - -
1 year - - - -

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

Index endpoint: L12_PEMPHIKELA – Severe bullous disorders, KELA reimbursement
GWS hits:

Survival analyses between endpoints

Plot

before Severe bullous disorders, KELA reimbursement
after Severe bullous disorders, KELA reimbursement

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Severe bullous disorders, KELA reimbursement